Treatment of Patients With Human Immunodeficiency Virus (HIV)-Related Chronic Diarrhea With Saccharomyces Boulardii or Placebo: A Double Blind Trial

Sponsor
Biocodex (Industry)
Overall Status
Completed
CT.gov ID
NCT00002088
Collaborator
(none)
100
1

Study Details

Study Description

Brief Summary

To assess the efficacy of Saccharomyces boulardii (a nonpathogenic yeast) in producing a significant reduction in diarrheal symptoms in HIV-infected patients with chronic diarrhea.

Condition or Disease Intervention/Treatment Phase
  • Drug: Saccharomyces boulardii
Phase 2

Study Design

Study Type:
Interventional
Masking:
Double
Primary Purpose:
Treatment
Official Title:
Treatment of Patients With Human Immunodeficiency Virus (HIV)-Related Chronic Diarrhea With Saccharomyces Boulardii or Placebo: A Double Blind Trial

Outcome Measures

Primary Outcome Measures

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No

    Inclusion Criteria

    Concurrent Medication:
    Allowed:
    • Antiviral medication for HIV infection.
    Patients must have:
    • Documented HIV infection.

    • Chronic diarrhea (for at least 1 month) that is either a manifestation or complication of documented HIV infection.

    • Had a stool culture (Salmonella, Shigella, Campylobacter, and Clostridium difficile) and stool analysis for ova and parasite (O/P X 3) within the past 2 months.

    • Failed antimicrobial treatment for diarrhea OR received no prior antimicrobials for stool pathogens because stool cultures were negative.

    Patients who are on antiviral medications for HIV infection must have received such medication for at least 2 weeks and must remain on stable dose for weeks 1 and 2 of study.

    Prior Medication:
    Allowed:
    • Prior antiviral medication for HIV infection (if on such medication, must have received it for at least 2 weeks).

    • Standard antimicrobial therapy for a documented positive gastrointestinal pathogen.

    Exclusion Criteria

    Concurrent Medication:
    Excluded:
    • Gastrointestinal medications that cause diarrhea (e.g., magnesium-containing antacids, lactulose).

    • Maintenance antifungal medication for life-threatening fungal infections (other than fluconazole <= 100 mg/day).

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Madison Clinic Seattle Washington United States 98104

    Sponsors and Collaborators

    • Biocodex

    Investigators

    • Study Chair: Surawicz CM,

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    , ,
    ClinicalTrials.gov Identifier:
    NCT00002088
    Other Study ID Numbers:
    • 083A
    First Posted:
    Aug 31, 2001
    Last Update Posted:
    Jun 24, 2005
    Last Verified:
    Mar 1, 1996

    Study Results

    No Results Posted as of Jun 24, 2005